Drug Database
RA

ranibizumab (RTPR 024 / RTPR024 / RanizuRel)

✓ Approved

Reliance Life Sciences Private Limited · VEGFA · 单克隆抗体

什么是 ranibizumab?

ranibizumab 是一种单克隆抗体,由Reliance Life Sciences Private Limited研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intraocular Injection。

药物档案

商品名RTPR 024, RTPR024, RanizuRel
公司Reliance Life Sciences Private Limited
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others), Intraocular Injection
状态Approved

作用机制

分子靶点

ranibizumab 作用于 1 个分子靶点:

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

ranibizumab 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Eye disordersNeovascular age-related macular degeneration✓ Approved

相关研究文献

PubMedEye (London, England)2026-11-19

Incidence and visual outcomes of post-intravitreal injection endophthalmitis: a single-centre analysis of 224,397 injections.

Kayikci Mahmutoglu Gulce G, Simsek Metehan M, Cevik Sadik Gorkem SG, Arici Murat M et al.

Post-injection endophthalmitis (PIE) is a rare, vision-threatening complication of intravitreal injections (IVIs). As IVI volumes rise globally, optimising prevention and management is crucial. This study evaluated PIE incidence, risk factors, microbiology, and outcomes over ten years. A retrospective cohort study of 224,397 IVIs. We analysed demographics, agent type, and preparation (pre-filled syringe [PFS] vs. manual aliquoting). Overall endophthalmitis incidence was 0.029% (n = 65), and 0.026% for anti-VEGFs. PFS-ranibizumab had the lowest incidence (0.014%) and was significantly safer than manually prepared bevacizumab (0.039%; OR: 2.74 [95% CI: 1.36-5.55], p = 0.003); vial-sourced aflibercept (0.027%) was intermediate and not statistically distinguishable from either. Culture positivity was 33.8% (n = 22), predominantly Gram-positive (81.8%), with Staphylococcus epidermidis being the most common (45.5%). In univariate analysis, culture positivity was the sole predictor of worse final visual acuity (VA) (p = 0.030), though limited by small sample sizes. Median VA worsened from 0.61 logMAR at baseline to 2.10 logMAR at presentation, recovering to 1.80 logMAR at final visit (p < 0.001). Among cases initially treated with tap and intravitreal antibiotics (TAI), 60% (21/35) required subsequent vitrectomy (PPV). No baseline clinical parameters predicted TAI success or PPV requirement (all p > 0.05). Dexamethasone implants, with their larger applicator, carried the highest risk. Among anti-VEGFs, PFS ranibizumab demonstrated the most favourable safety profile, with the lowest incidence of PIE. Manual immediate-use bevacizumab aliquoting is a safe, cost-effective alternative in resource-limited settings. In univariate analysis, culture positivity emerged as a negative prognostic factor, though this finding is limited by small sample sizes. Given unpredictable TAI responses, aggressive monitoring and a low PPV threshold are essential.

PMID 43052414
阅读全文 →
PubMedCureus2026-11-18

Correlation Between Serum Vascular Endothelial Growth Factor-A (VEGF-A) Levels and Optical Coherence Tomography Angiography Parameters in Exudative Age-Related Macular Degeneration.

Sodhi Punita K PK, Doddaiah Divya D, Parvinbhai Hitenkumar Miyani HM, Kunhani Anjali A et al.

Among inflammatory and angiogenic cytokines, VEGF-A has been recognized as a driver of increased vascular permeability in eyes with exudative age-related macular degeneration (ExARMD). The study aimed to evaluate the correlation between serum vascular endothelial growth factor-A (VEGF-A) levels and optical coherence tomography angiography (OCTA) parameters in ExARMD. In this prospective, single-arm, before-and-after interventional study, treatment-naïve eyes with ExARMD underwent assessment of best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), and OCTA parameters, including foveal avascular zone (FAZ) and vessel density (VD) of different slabs of retina and choroid. The serum VEGF-A levels were measured with commercially supplied enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's protocol. Correlations between serum VEGF-A levels and ocular parameters were evaluated before and at one month after a single intravitreal injection of 0.5 mg/0.05 mL ranibizumab biosimilar. The study involved 36 eyes from 25 ExARMD patients, with a mean age of 63.9 ± 7.68 years. At baseline, the distance BCVA was LogMAR 1.1 ± 0.6, CFT was 367.0 ± 237.1 (median: 294.0 (IQR: 219.5 to 395.0)) microns, SFCT was 262.9 ± 71.6 (median: 263.5 (IQR: 223.0 to 292.0)) microns, and serum VEGF-A levels were 221.1 (IQR: 130.0 to 355.7) pg/mL. Before treatment, VEGF-A levels correlated negatively with CFT (Rho = -0.236) and FAZ perimeter (Rho = -0.039) but positively with LogMAR BCVA (r = 0.190), SFCT (r = 0.243), FAZ area (Rho = 0.153), circularity (r = 0.437), and VD of most retino-choroidal layers. One month after treatment, the distance BCVA was LogMAR 0.8 ± 0.5, CFT was 324.9 ± 208.0 (median: 284.0 (IQR: 183.5 to 426.5) microns, SFCT was 240.4 ± 68.5 (median: 241.5 (IQR: 180.0 to 288.5) microns, and serum VEGF-A levels were 207.2 (IQR: 106.3 to 423.9) pg/mL. The VEGF-A levels correlated negatively with FAZ area (Rho = -0.016), perimeter (Rho = -0.033), and circularity (r = -0.170) but positively with LogMAR BCVA (r = 0.025), CFT (r = 0.032), SFCT (Rho = 0.239), and VD of most retino-choroidal layers. None of the correlations were significant after applying Bonferroni correction. In an exploratory unadjusted analysis, higher serum VEGF-A was associated with worse visual acuity (VA), increased SFCT, reduced FAZ perimeter, and increased VD of most retino-choroidal layers, though the association was weak. The correlation between serum VEGF-A levels and CFT, FAZ area, and circularity changed direction following treatment. After Bonferroni correction for multiple comparisons, none of these associations remained statistically significant.

PMID 43048476
阅读全文 →
PubMedActa ophthalmologica2026-11-17

Intravitreal dexamethasone implant-based versus ranibizumab-based regimens for stage 3 Coats' disease: Efficacy and complications.

Zhang Juan J, Zhang Meng M, Yang Qian Q, Chang Qing Q et al.

To compare the efficacy of intravitreal dexamethasone (DEX) implant-based regimen versus ranibizumab-based regimen for managing retinal exudation and complications in stage 3 Coats' disease. Thirty-seven eyes with stage 3 Coats' disease were enrolled and followed for 24 months: 16 received DEX implants and 21 received ranibizumab as initial treatments. Outcomes included changes in retinal exudation clocks and central foveal thickness (CFT), exudative retinal detachment (ERD) resolution, changes in best-corrected visual acuity (BCVA) and complications. The DEX implant reduced retinal exudation clocks and CFT more effectively than ranibizumab at 1, 2 and 3 months (all p < 0.05). Significantly more eyes in the DEX implant group achieved exudate absorption and complete ERD resolution within 12 months without additional surgeries (both p < 0.05). The BCVA improvement was superior in the DEX implant group than in the ranibizumab group (87.5% vs. 14.29%, p < 0.001). Elevated intraocular pressure occurred in 25.0% of DEX-treated eyes and was managed medically. Cataract surgery rates were higher in the DEX group at 12 months but comparable at 24 months. Tractional retinal detachment (TRD) and epiretinal membrane (ERM) occurred more frequently in the ranibizumab group (p = 0.003 and 0.017, respectively), and more eyes in the ranibizumab group needed additional pars plana vitrectomy by 24 months. The DEX implant group achieved superior anatomic and functional outcomes compared with the ranibizumab group for stage 3 Coats' disease, with fewer vision-threatening complications such as TRD and ERM. The DEX implant may be a promising adjuvant therapy for stage 3 Coats' disease.

PMID 43042711
阅读全文 →
PubMedGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026-11-17

Platelet parameters and treatment-requiring reactivation after intravitreal ranibizumab for retinopathy of prematurity: a retrospective single-center study.

Zhou Yanan Y, Xiao Bo B, Wang Shuanglian S

To investigate whether platelet parameters are associated with the need for retreatment in preterm infants with retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR). This retrospective, single-center study included preterm infants with zone II stage 3 + ROP who received primary IVR. Platelet count (PC), mean platelet volume (MPV), and platelet mass index (PMI) were collected at birth, at first treatment, and at 4 weeks post-treatment. Infants were divided into a retreatment group (n = 40) and a control group (n = 143, no retreatment). Multivariable logistic regression and receiver operating characteristic (ROC) curve analysis were performed. Of 183 infants, 40 (21.86%) required retreatment. The postmenstrual age (PMA) at retreatment was 41.09 ± 1.72 weeks, and the median time to retreatment was 7.36 weeks (interquartile range [IQR]: 6.47-8.00). Birth weight (BW), gestational age (GA), and PMA at initial treatment were significantly lower in the retreatment group (all P < 0.001). At birth, PC was lower and MPV was higher in the retreatment group (both P < 0.001), whereas PMI did not differ (P = 0.095). At first treatment, PC and PMI were lower in the retreatment group (both P < 0.001), while MPV did not differ (P = 0.319). At 4 weeks post-treatment, PC and PMI remained lower and MPV was higher in the retreatment group (P < 0.001, P < 0.001, and P = 0.039, respectively). In the multivariable model, PMA at initial treatment (odds ratio [OR] = 0.113, 95% confidence interval [CI]: 0.029-0.435, P = 0.002) and PC at birth (OR = 0.917, 95% CI: 0.870-0.966, P = 0.001) were independent protective factors, whereas MPV at birth (OR = 14.252, 95% CI: 2.340-86.791, P = 0.004) was an independent risk factor. The area under the curve (AUC) was 0.886 for PC (cut-off ≤ 271.50 × 10⁹/L; sensitivity 75.0%, specificity 99.3%) and 0.886 for MPV (cut-off ≥ 10.550 fL; sensitivity 70.0%, specificity 97.2%). PC at birth and MPV at birth are independently associated with the need for retreatment after IVR for ROP. These readily available hematological markers warrant further investigation as potential indicators for identifying infants requiring closer follow-up.

PMID 43043434
阅读全文 →
PubMedCureus2026-11-16

Visual and Anatomical Outcomes of Branch Retinal Vein Occlusion in Routine Care: A Retrospective Study of 102 Eye Records.

Bernstein Suki S, Berdejo Cora C

Background Branch retinal vein occlusion (BRVO) can cause visual loss through macular oedema. Routine-care outcomes reflect heterogeneous treatment histories and follow-up. This study evaluated visual and anatomical changes and their association in a district-hospital BRVO cohort. Methods We retrospectively analysed 102 eye records classified into 11 treatment pathways within a five-year period from January 2019 to December 2023. Visual acuity (VA), recorded in letters, and five-field average optical coherence tomography (OCT) thickness were compared between baseline and the last recorded appointment with a minimum of four weeks of follow-up. Mean changes were calculated with 95% confidence intervals (CIs). Pearson and Spearman correlations assessed the association between VA gain and OCT thickness reduction. Treatment groups were described without causal comparisons. Results Median follow-up was 23 months (interquartile range, 12-38.5; range, 2-73). Mean VA increased from 60.0 ± 17.0 to 72.3 ± 13.8 letters; mean change was 12.3 ± 16.7 letters (95% CI, 9.0-15.5). Mean five-field average OCT thickness declined from 414.5 ± 109.5 to 300.5 ± 55.7 µm; mean reduction was 113.9 ± 125.2 µm (95% CI, 89.4-138.5). Forty-two eye records (41.2%) gained at least 15 letters, and four (3.9%) lost at least 15 letters. VA gain correlated with thickness reduction (Pearson r = 0.54; 95% CI, 0.38-0.66; Spearman ρ = 0.59). Exclusion of two zero-letter baseline records yielded a mean gain of 11.8 ± 16.5 letters. The aflibercept and ranibizumab categories comprised 35 and 30 records, respectively. Conclusions Visual improvement and reduced five-field average OCT thickness were observed during routine BRVO care, with a moderate association between functional and anatomical change. Ranibizumab showed the largest mean VA gain amongst the single-agent treatment groups, exceeding the observed aflibercept. Variable follow-up, small treatment subgroups, and non-random treatment selection limit comparative interpretation. The findings support assessing vision and retinal anatomy together and do not establish superiority of any treatment pathway.

PMID 43036601
阅读全文 →
PubMedEye (London, England)2026-11-16

Real-world outcomes following 15 years of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration.

Phan Long T LT, Broadhead Geoffrey K GK, Spooner Kimberly L KL, Fraser-Bell Samantha S et al.

To evaluate visual and anatomical outcomes in eyes with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (anti-VEGF) therapy over 15-years in a real-world setting. A retrospective cohort study was conducted. Eyes with nAMD that began ranibizumab treatment between 2006 and 2009 were assessed for eligibility which required ≥ 15 years of continuous follow-up, and no prior photodynamic therapy or earlier anti-VEGF use. A total of 1202 eyes were evaluated, of which 107 met the eligibility criteria. Medical records and corresponding optical coherence tomography scans were evaluated to assess changes from baseline in visual acuity (VA), central macular thickness (CMT), anatomic findings, injection frequency, and adverse events. Mean age was 69 ± 8.7 years and mean VA was 58.4 ± 16.6 letters at treatment initiation. At year 15, mean VA change from baseline was -8.5 letters (p < 0.001, 95% CI -13.4 to -3.6). The proportion of eyes with VA 20/40 or better was 32%, and the proportion of eyes with VA worse than or equal to 20/200 was 31%. Subretinal fibrosis was present in 43% of eyes, and macular atrophy was present in 74% of eyes, 67% of which were sub-foveal. Subretinal fibrosis, sub-foveal macular atrophy, and treatment discontinuation were each associated with final VA in multivariate analysis. Anti-VEGF therapy was associated with early anatomical improvements and long-term visual preservation in a meaningful proportion of eyes with nAMD over 15 years. Macular atrophy and fibrosis were strongly associated with poorer visual outcomes.

PMID 43035550
阅读全文 →

注册免费账户还可查看另外 5691 篇文献

免费注册查看全部文献 →

了解更多ranibizumab